WASHINGTON, D.C. — The Food and Drug Administration (FDA) this week approved a new vaccine, Capvaxive, to combat invasive diseases and pneumonia caused by Streptococcus pneumoniae in adults.

This article will discuss pneumococcal disease, the available vaccines, side effects, and more. Pneumococcal disease is caused by a bacterium called Streptococcus pneumoniae. This bacterium can ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results ... a strong immune response against all 31 serotypes of Streptococcus pneumoniae included in the formulation, in adults aged ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Vaccination with CAPVAXIVE may not protect all vaccine recipients. About pneumococcal disease Pneumococcal disease is an infection caused by a bacteria called Streptococcus pneumoniae. There are ...

Chief Medical Officer of Northwestern Medicine’s Northwest region of hospitals Dr. Irfan Hafiz joins Bob Sirott to talk about who should get the pneumonia vaccine, a study of the impact of the ...